Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07636161 · ClinicalTrials.gov registry record · Phase 4
PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)
A Phase 4 study, sponsored by University of Miami.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07636161 is a Phase 4 study that has not yet begun recruiting, run by University of Miami. The registered enrollment target is 30 participants.
The verdict
NCT07636161, a Phase 4 study, has not yet begun recruiting, sponsored by University of Miami.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this research study is to look at whether Eroxon® gel when used together with tadalafil, may help improve erectile function in men ages 18 to 40 who have type 2 diabetes.
Interventions
- DRUG tadalafil
- DEVICE Eroxon®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-09 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07636161
The ClinicalTrials.gov registry entry for NCT07636161 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tadalafil is the first listed.
NCT07636161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07636161 about?
NCT07636161 is a clinical study titled "PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)". The purpose of this research study is to look at whether Eroxon® gel when used together with tadalafil, may help improve erectile function in men ages 18 to 40 who have type 2 diabetes.
What is the current status of trial NCT07636161?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-09. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07636161?
The interventions under investigation include: tadalafil (DRUG), Eroxon® (DEVICE).
Who is sponsoring clinical trial NCT07636161?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.